Belite Bio to Participate in Four Upcoming Investor Conferences

Core Insights - Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs [2] - The company is actively participating in four upcoming investor conferences to present its developments and engage with investors [1][3] Company Overview - Belite Bio targets diseases such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) associated with advanced dry age-related macular degeneration (AMD) [2] - The lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently undergoing multiple clinical trials, including a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) for STGD1, as well as a Phase 3 study (PHOENIX) for GA [2] Upcoming Events - The company will present at the Deutsche Bank Depositary Receipts Virtual Investor Conference on May 15, 2025, at 12:30 pm ET [3] - A fireside chat is scheduled for May 20, 2025, at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ [3] - Another fireside chat will take place on May 27, 2025, at the Stifel 2025 Ophthalmology Forum [3] - The Benchmark's Healthcare House Call One-on-One Conference will feature a fireside chat on May 29, 2025, at 12:45 pm ET [3]